StockGuru Spotlight on Amarantus Bioscience Holdings, Inc.
(Symbol: AMBS)
Help us update information on this company. Email any updates to: [email protected]
About Amarantus Bioscience Holdings, Inc.:
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine (Eltoprazine), a phase 2b ready small molecule indicated for Parkinson’s Levodopa induced dyskinesia and Adult ADHD. AMBS has an elxclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson’s disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard).
Where it is located:
c/o Janssen Labs @QB3
953 Indiana Street
San Francisco, CA
94107
United States
Key Executive Contact:
John W. Commissiong
CSO
Ninety Day Volume:
9948417 (as of date of publication)
Ninety Day Dollar Volume:
$1,173,913
Share Information:
756714307 shares as of 2014-08-14
Corporate Information:
State Incorporated: NV
Country Incorporated: USA
Contact, Website and Social Media for Amarantus Bioscience Holdings, Inc.:
Shown Where Available
Website: http://www.amarantus.com
Facebook: https://www.facebook.com/amarantusbio
Twitter: http://www.twitter.com/amarantusbio
LinkedIn: http://www.linkedin.com/company/amarantus-biosciences
Telephone: (408) 737-2734
Email: [email protected]
Investor Relations for Amarantus Bioscience Holdings, Inc.:
LHA Inc.